Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GS-5885 + GS-9451 with tegobuvir and/or ribavirin in treatment-experienced genotype 1 hepatitis C
2011-002748-28Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hepatitis C (CHC) comparing GS-5885 + GS-9451 + tegobuvir + ribavirin, GS-5885 + GS-9451 + tegobuvir and GS-5885 + GS-9451 + ribavirin (3 arms). Primary endpoint: Sustained virologic response at 24 weeks post-treatment. Started Aug 2011; status: completed.
02
Drugs
ledipasvirvedroprevirtegobuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-002748-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002748-28.